Assistant Professor

Pages of interest

Related News

Link to:Clearing the Air: Catherine Hausman details methane gas regulatory impacts
Nov 01, 2018
Over the past year energy policy standards have been relaxed by the federal government, justified by supporters in the[...]
Link to:Potter publishes op-ed in The Guardian on increasing threat of terrorism in China
May 08, 2014
In the wake of three terrorist attacks by Uighur militants in China in the past two months, Assistant Professor Phil[...]
Link to:Phil Potter quoted by Wall Street Journal and Dow Jones Business News on Chinese terror attack
May 01, 2014
Philip B.K. Potter, assistant professor at the Ford School, was quoted in a May 1 Wall Street Journal article on the[...]
Link to:Michigan Daily article cites CLOSUP panel on Proposition 3
Oct 18, 2012
An article in the Michigan Daily, entitled "Michigan voters divided on Proposition 3," cited a panel discussion hosted[...]
Link to:Extreme poverty: 2.8 million children in the U.S. live on  per day
Feb 24, 2012
A new report indicates that one in five households with children in poverty are surviving on the cash equivalent of a[...]

Related Past Events

Sep
09
From the speaker's bio: William Inboden is a Distinguished Scholar at the Strauss Center for International Security and Law and an Assistant Professor at the LBJ School of Public Affairs at the University of Texas-Austin. He is a Non-Resident Fellow with the German Marshall Fund of the United States, and will also serve as Executive Director of the William P. Clements Jr. Center on History, Strategy and Statecraft at the University of Texas at Austin.
2013 - 11:30 am to 1:00 pm
Sep
14
Should there be boundaries to patentable subject matter? What happens if the patents stifle innovation, rather than promoting it? How should we proceed if patents negatively influence health care, rather than enhancing it? The panel will discuss these questions by focusing on the controversy over patents on the breast and ovarian cancer (BRCA) genes, which led to a current ACLU class-action lawsuit against the U.S. Patent and Trademark Office and Myriad Genetics.
2009 - 4:00 pm to 5:30 pm